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Abstract
It has been recently reported that the p.His63Asp polymorphism of the HFE gene accelerates 
disease progression both in the SOD1 transgenic mouse and in amyotrophic lateral sclerosis (ALS) 
patients. We have evaluated the effect of HFE p.His63Asp polymorphism on the phenotype in 
1351 Italian ALS patients (232 of Sardinian ancestry). Patients were genotyped for the HFE 
p.His63Asp polymorphism (CC, GC, and GG). All patients were also assessed for C9ORF72, 
TARDBP, SOD1, and FUS mutations. Of the 1351 ALS patients, 363 (29.2%) were heterozygous 
(GC) for the p.His63Asp polymorphism and 30 (2.2%) were homozygous for the minor allele 
(GG). Patients with CC, GC, and GG polymorphisms did not significantly differ by age at onset, 
site of onset of symptoms, and survival; however, in SOD1 patients with CG or GG polymorphism 
had a significantly longer survival than those with a CC polymorphism. Differently from what 
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observed in the mouse model of ALS, the HFE p.His63Asp polymorphism has no effect on ALS 
phenotype in this large series of Italian ALS patients.
Keywords
Amyotrophic lateral sclerosis; HFE polymorphisms; phenotype; survival; SOD1
1. Introduction
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder of adult life 
characterized by a progressive loss of upper (cortical) and lower (bulbar and spinal) motor 
neurons. The disease has an invariably fatal course over a period of 3–5 years. No disease-
modifying therapy is available, with the exception of riluzole, an antiexcytotoxic drug that 
prolongs patients' life by 3 months. The cause of ALS is still unknown. About 10% of ALS 
patients have a family history of ALS or frontotemporal dementia whereas in ~90% of cases 
the disease appears sporadically in the population. The most common genes related to ALS 
are C9ORF72, SOD1, TARDBP, and FUS, but at least 20 other rarer genes have been 
identified (Finsterer and Burgunder, 2014 and Renton et al., 2014). In addition, some genes 
have been found to modify the phenotype or the survival of ALS.
Polymorphisms of Unc-13 homolog A (UNC13 A) (Chiò et al., 2013 and Diekstra et al., 
2012) of nonimprinted in Prader-Willi and Angelman syndrome 1 (NIPA1) (Blauw et al., 
2012) genes and polyQ intermediate-length expansion of ATXN2 (Chiò et al., 2014) have 
been associated with a shorter survival, whereas a locus on 1p34.128 has been associated 
with a younger age at onset (Ahmeti et al., 2013).
Recently, it has been reported that the p.His63Asp polymorphism of the HFE gene 
accelerates disease progression in the ALS SOD1 transgenic mouse (Nandar et al., 2014). 
Conversely, in a small study on 35 ALS patients, it has been reported that patients carrying 
the p.H63D polymorphism of the HFE gene had a significantly longer survival than those 
with the wild-type gene (Su et al., 2013).
The aim of this study was to assess the influence of the p.H63D polymorphism of the HFE 
gene on the phenotype and survival of a large series of ALS patients of Italian and Sardinian 
ancestry.
2. Methods
2.1. Cases
ALS cases were collected through the Italian ALS Genetic (ITALSGEN) and the Sardinian 
ALS Genetic (SARDINIALS) consortia (Chiò et al., 2012 and Chiò et al., 2014). Cases were 
patients with definite, probable, probable-laboratory supported, and possible ALS diagnosed 
between 2006 and 2012. A total of 149 cases have been already reported (Restagno et al., 
2007). All cases were also screened for most common ALS genes, that is, C9ORF72, SOD1, 
TARDBP, and FUS.
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2.2. Controls
There were 1302 Italian and 121 Sardinian subjects without neurologic disorders, age- and 
gender-matched to cases. Of these, 162 Italian subjects have been previously reported 
(Restagno et al., 2007).
2.3. Genotyping
Cases and controls were genotyped using the Illumina NeuroX SNP array. The NeuroX 
platform consists of standard Illumina exome content of approximately 240,000 variants and 
over 24,000 custom content variants focusing on neurologic diseases (Nalls et al., 2015). 
Quality control parameters for genotype calling and filtering are as previously described 
(Nalls et al., 2015). Genotypes for rs1799945 (chr6:26091179, C > G, build 37) were 
extracted from the larger NeuroX dataset. SNP genotypes were not confirmed on another 
platform such as Sanger sequencing. However, the quality of genotyping has been assessed 
using Polar and Cartesian cluster plots for SNP rs1799945; the quality control metric of 
genotyping accuracy for this SNP was 0.835, indicating a high level of precision in 
assigning genotypes to samples (Supplementary Fig. 1).
2.4. Statistical methods
Comparisons between means were made with the Student's t-test or analysis of variance; 
comparison between categorical variables was made with the χ2 test; Levene's test was used 
to confirm the equality of variances. Survival was calculated from onset to death/
tracheostomy or censoring date (October 31, 2014) using the Kaplan-Meier survival 
modeling, and differences in survival were measured by the log-rank test. No patients were 
lost to follow up. Multivariable analysis was performed with the Cox proportional hazards 
model (stepwise backward) with a retention criterion of p < 0.1. The significance level was 
set at p < 0.05. Data were processed using SPSS statistical package, version 22.0 (IBM 
Corporation, Chicago, IL, USA).
2.5. Ethical approval
The study has been approved by the ethical committees of the involved centers. All patients 
and controls signed a written informed consent. Databases were treated according to the 
Italian regulations for privacy.
3. Results
A total of 1119 Italian and 232 Sardinian ALS patients have been included in the study. 
Patients' clinical characteristics and genetic mutations are reported in Table 1.
3.1. HFE genotyping
The frequency of CC, GC, and GG genotypes in Italian and Sardinian ALS cases and 
controls is reported in Table 2. No significant differences were found in either population. 
Genotype frequencies are respected Hardy-Weinberg equilibrium in both cohorts (not 
shown).
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3.2. Clinical characteristics of patients with different genotypes
Patients with CC, GC, and GG genotypes did not differ by age at onset and site of onset 
(Table 3 and Table 4). No difference of survival was found considering both the CC/GC/GG 
phenotypes and the presence of a G allele in either cohorts of patients (Fig. 1 and Fig. 2). 
This finding has been confirmed in Cox multivariable analysis.
We also assessed the possible effect of HFE phenotypes in patients carrying genetic 
mutations. A list of identified genetic mutations is reported in Supplementary Table 1. No 
difference was found in the groups of patients carrying C9ORF72, FUS, and TARDBP 
mutations. In the 26 patients with SOD1 mutations, we found an increased survival in 
patients with GC or GG compared with CC genotypes or in patients carrying the G allele 
(dominant assumption) (p = 0.04; Fig. 3). This finding is confirmed by the multivariable Cox 
model, where the G is retained as an independent prognostic factor (p = 0.03). A list of all 
SOD1 mutated cases with clinical details and HFE status is reported in Table 5.
4. Discussion
In 2 cohorts of Italian and Sardinian patients, we have found that the p.H63D polymorphism 
of the HFE gene does not represent a risk factor for ALS. Moreover, we showed that the 
presence of the G allele does not modify the overall patients' clinical phenotype and survival. 
However, patients with SOD1 mutations carrying the G allele had a better survival than other 
patients. In subjects with C9ORF72, TARDBP, and FUS mutations, the p.H63D 
polymorphism did not modify the phenotype and survival.
Several articles have suggested that the p.H63D polymorphism of HFE represents a risk 
factor for ALS (Goodall et al., 2005, Restagno et al., 2007 and Sutedja et al., 2007), but 
others did not confirm this finding; 2 meta-analyses of literature arrived at opposite 
conclusions (Li et al., 2014 and van Rheenen et al., 2013). This discrepancy may arise from 
several reasons: first, some articles are based on small, underpowered series; second, in 
some studies controls are not matched by ethnic origin to cases. A meta-analysis of 
worldwide HFE genotypes showed that the frequency of G polymorphism ranges from 30% 
in southern Europe, 20% in northern Europe, 15% in the Indian subcontinent, 5% in China, 
and 5% in sub-Saharan Africa (Hanson et al., 2001). Interestingly, the minor allele 
frequency observed for rs1799945 among the Italian samples analyzed in the present study 
(723 G alleles of 4842 alleles; minor allele frequency = 0.149) is comparable to its 
frequency reported in the ExAC browser (9128 G alleles of 66,738 alleles; minor allele 
frequency = 0.137; http://exac.broadinstitute.org/variant/6-26091179-C-G, accessed June 6, 
2015).
In our 2 large cohorts of patients of Italian and Sardinian ancestry, compared with regionally 
matched controls, we have found that the p.H63D polymorphism of HFE does not increase 
the risk of developing ALS.
Recently, an article on a small series of ALS patients reported a significantly increased 
survival of subjects carrying the G allele compared with those who were homozygous for the 
C allele of the HFE gene (Su et al., 2013). The authors also found that the presence of the G 
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allele was associated with a reduction of SOD1 activity in the muscle and that SOD1 protein 
expression was negatively associated with total disease duration in ALS patients. In a 
subsequent article, the same group reported that a double transgenic mouse line (SOD1/
H67D) carrying the H67D HFE (homolog of human H63D) and SOD1 (G93A) mutations 
have a shorter survival and an accelerated disease progression (Nandar et al., 2014); they 
therefore concluded that when HFE is combined with a mutation in an ALS gene the disease 
duration could be negatively impacted. The authors suggested that H63D HFE 
polymorphism can modify ALS pathophysiology via pathways involving oxidative stress, 
gliosis, and disruption of cellular functions.
Previously, the relationship between survival and HFE polymorphisms had been assessed 
only in a French series of ALS patients with negative results (Praline et al., 2012). However, 
in this article, no distinction between patients carrying or not-carrying SOD1 mutations was 
made.
In our series, we found that in both populations the presence of a G allele or GG/GC 
phenotypes did not influence overall patients' survival. We also looked at the patients 
carrying mutations of major ALS genes. No effect of HFE status was found in patients with 
C9ORF72, TARDBP, and FUS mutations. Conversely, in patients with SOD1 mutations the 
presence of a G allele was found to be significantly associated with a longer survival. This 
finding is in contrast with the reported shorter survival in the double transgenic mouse line 
(SOD1/H67D) (Nandar et al., 2014), highlighting the possibility that genetic interactions in 
mice compared with humans are biologically different. However, because of the small 
number of patients carrying a SOD1 mutation in this series, our finding should be 
considered with caution, because of the possibility of a type 1 error.
In conclusion, we found that in 2 large cohorts of Italian and Sardinian patients, HFE 
p.H63D polymorphism is not a risk factor for ALS and does not modify the phenotype and 
survival of patients with ALS. However, we found a possible interaction between the 
presence of a SOD1 genetic mutation and HFE genotype, with better survival in subjects 
carrying the G allele. Although based on a small cohort of patients, this interaction warrants 
further studies to better understand the genetic mechanisms underlying ALS.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Fig. 1. Italian patients
Survival curves by HFE genotype. CC, median survival time 3.0 years (interquartile range 
1.9–5.5); GC/GG, median survival time 3.4 years (interquartile range 2.0–6.7). p = n.s. CC, 
blue; GC/GG green.
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Fig. 2. Sardinian patients
Survival curves by HFE genotype. CC, median survival time 4.7 years (interquartile range 
2.4–14.2); GC/GG, median survival time 3.5 years (interquartile range 2.3–10.3). p = n.s. 
CC, blue; GC/GG green.
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Fig. 3. Italian patients carrying SOD1 mutations
CC, median survival time 2.1 years (interquartile range 2.6–8.4); GC/GG, median survival 
time 15.3 years (interquartile range 1.2–15.3). p = 0.04. CC, blue; GC/GG green.
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Table 1
Clinical characteristics of Italian and Sardinian ALS cases
Italian ALS, n =
1119
Sardinian ALS, n =
232
Gender (female, %) 494 (44.1%) 92 (39.7%)
Mean age at onset
(years)
62.2 (11.7) 60.5 (12.1)
Site of onset (Bulbar,
%)
299 (26.7%) 48 (20.7%)
Genetic mutations
Wild Type 1021 (91.2%) 139 (59.9%)
C9ORF72 50 (4.5%) 23 (9.9%)
SOD1 24 (2.1%) 2 (0.9%)
TARDBP 10 (0.9%) 68 (29.3%)
FUS 14 (1.3%) 0
Key: ALS, amyotrophic lateral sclerosis.
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Table 3
Mean age at onset according to HFE H63D genotype
CC GC GG p Value
Mean age at onset
Italians 62.3
(11.2)
62.2
(11.7)
62.5
(11.2)
0.92
Sardinians 60.2
(12.8)
60.6
(10.5)
65.4
(10.3)
0.78
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Table 4
Site of symptom onset according toHFE H63D genotype
Site of symptom
onset
CC GC GG p Value
Italians
Bulbar 216 78 5 0.91
Spinal 588 215 17
Sardinians
Bulbar 31 15 2 0.93
Spinal 123 55 6
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